Fisher, Jack G. http://orcid.org/0000-0002-5090-7503
Doyle, Amber D. P. http://orcid.org/0000-0003-3235-5570
Graham, Lara V.
Sonar, Shreyanshi
Sale, Ben http://orcid.org/0000-0003-3292-1886
Henderson, Isla
Del Rio, Luis
Johnson, Peter W. M. http://orcid.org/0000-0003-2306-4974
Landesman, Yosef
Cragg, Mark S. http://orcid.org/0000-0003-2077-089X
Forconi, Francesco http://orcid.org/0000-0002-2211-1831
Walker, Christopher J.
Khakoo, Salim. I.
Blunt, Matthew D. http://orcid.org/0000-0003-1099-3985
Funding for this research was provided by:
RCUK | Medical Research Council (DTP award MR/N014308/1, MR/MO19829/1)
John Goldman Fellowship from Leukaemia UK Cancer Immunology Fund
Cancer Research UK (ECRIN-M3 accelerator award C42023/A29370)
Article History
Received: 9 March 2023
Revised: 3 July 2023
Accepted: 21 July 2023
First Online: 1 August 2023
Change Date: 4 August 2023
Change Type: Update
Change Details: The supertitle has been corrected.
Competing interests
: CJW and YL are employees and stockholders of Karyopharm Therapeutics. MDB received research funding from Karyopharm Therapeutics. Karyopharm Therapeutics reviewed the manuscript prior to submission for publication. MSC is a retained consultant for BioInvent International and has performed educational and advisory roles for Roche, Boehringer Ingelheim, Baxalta, Merck KGaA and GLG. He has received research funding from Bioinvent, Roche, Gilead, iTeos, UCB and GSK. FF has received research support from Abbvie and has performed consultancies or educational activities for AstraZeneca, AbbVie, Janssen-Cilag, BC-Platform and Beigene. No conflicts of interest were disclosed by the other authors.